Small molecule · Antagonist of endothelin type A receptor (EDNRA) and angiotensin II type 1 receptor (AGTR1) · developed by Travere
Sparsentan is an oral dual antagonist of the endothelin type A receptor and the angiotensin II type 1 receptor. By blocking both receptors, it counters endothelin-1 and angiotensin II effects such as vasoconstriction, podocyte injury and fibrosis. It is studied in immunoglobulin A nephropathy, focal segmental glomerulosclerosis, proteinuria, kidney transplant and hypertension.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07219121 | Phase 4 | Proteinuria | Active not recruiting | TVTX |
| NCT01613118 | Phase 2 | Focal Segmental Glomerulosclerosis | Completed | TVTX |
| NCT00522925 | Phase 2 | Hypertension | Completed | LGND |
| NCT05562362 | Phase 1 | Healthy Subjects | Completed | TVTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Immunoglobulin A (IgA) NephropathyKidney TransplantProteinuriaFocal Segmental GlomerulosclerosisHealthy SubjectsHypertension
Updated Nov 15, 2026. Something wrong or missing? Report it on the TVTX page.
See TVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TVTX catalysts and pipeline →